Fig. 7

LA-ISA vaccination induces antitumour immune activities in HLA-A2.1⁺/ECM1⁺ allograft tumour-bearing HLA-A2.1 transgenic mice. a Epitope vaccination pattern diagram. HLA-A2.1 and human ECM1 double-knock-in mouse mammary cancer cell line (E0771) was subcutaneously injected into HLA-A2.1 transgenic mice to construct the allograft tumour model. LA- or YL-ISA was inoculated into HLA-A2.1 transgenic mice for three times. The dose of LA or YL was 1 mg/20 g body weight. TAK242 diluent in normal saline was injected intravenously into HLA-A2.1 transgenic mice at a dose of 1 mg/kg 3 h before epitope-ISA vaccination. b The frequencies of CD8⁺ T and NK cells (CD49b⁺) in splenocytes as well as the expression level of Rae1 in DCs from HLA-A2.1 transgenic mice were detected by flow cytometry (n = 3). c Immunohistochemistry assay of ECM1 and HLA-A2 in tumour tissues. Scale bars, left panel, 100 μm, right panel, 50 μm. d The transplanted tumours were removed surgically at day 25 post-tumour implantation. e Growth curve of transplanted HLA-A2.1⁺/ECM1⁺ murine tumours (n = 6). f The weight of transplanted HLA-A2.1⁺/ECM1⁺ murine tumours at day 25 after tumour cell inoculation (n = 6). g Survival (n = 6). AVG, average; LER (%), life extension rate. Control, transgenic mice inoculated with normal saline. b, e, f P values were obtained with independent-samples t-test; error bars denote standard deviation (SD). b, f ^**P < 0.01, ^***P < 0.001, NS, not significant. e Compared with control, ^**P < 0.01; compared with ISA, ^##P < 0.01; compared with YL-ISA, ^&&P < 0.01; compared with LA-ISA + TAK242, ^$$P < 0.01. g P values calculated by the log-rank test; compared with control, ^***P < 0.001; compared with ISA, ^##P < 0.01; compared with YL-ISA, ^&P < 0.05; Compared with LA-ISA + TAK242, ^$$P < 0.01